{
    "root": "e4c5fe1d-4ca1-9fdc-68ed-a5bf3b29b85a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ONDANSETRON",
    "value": "20250307",
    "ingredients": [
        {
            "name": "ONDANSETRON HYDROCHLORIDE",
            "code": "NMH84OZK2B"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "Hypromellose 2910 (5 Mpa.S)",
            "code": "R75537T0T4"
        },
        {
            "name": "lactose monohydrate",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "magnesium stearate",
            "code": "70097M6I30"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "Polyethylene Glycol, Unspecified",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "titanium dioxide",
            "code": "15FIX9V2JP"
        },
        {
            "name": "Hypromellose 2910 (6 Mpa.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        }
    ],
    "indications": "Ondansetron  tablets are indicated for the prevention of nausea and vomiting associated with: \n                  \n                     \n                        highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m2 .\n                        \n                     \n                     \n                         initial and repeat courses of moderately emetogenic cancer chemotherapy.\n                        \n                     \n                     \n                        radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen\n                     \n                  \n                  Ondansetron tablets are also indicated for the prevention of postoperative nausea and/or vomiting.",
    "contraindications": "See full prescribing information for the recommended dosage in adults and pediatrics (2) Patients with severe hepatic impairment: do not exceed a total daily dose of 8 mg ( 2.2 , 8.6 )",
    "warningsAndPrecautions": "Ondansetron Tablets\n                  \n                  Ondansetron Tablets Ondansetron tablets USP, 4 mg (ondansetron hydrochloride USP, equivalent to 4 mg of ondansetron) are white, round, biconvex, film coated tablets debossed “R” on one side and “153” on other side and are supplied in bottles of 30, 100, 500, unit-dose packages of 100 (10 x 10) and unit-dose packages of 3 (1 x 3).   \n                  Bottles of 30 NDC 55111-153-30 \n                  Bottles of 100 NDC 55111-153-01 \n                   Bottles of 500 NDC 55111-153-05 \n                  Unit Dose Packages of 100 (10 x 10) NDC 55111-153-78 \n                   Unit Dose Packages of 3 (1 x 3) NDC 55111-153-13   \n                   Ondansetron tablets USP, 8 mg (ondansetron hydrochloride USP, equivalent to 8 mg of ondansetron) are yellow, round, biconvex, film coated tablets debossed “R” on one side and “154” on other side and are supplied in bottles of 30, 100, 500, unit-dose packages of 100 (10 x 10) and unit-dose packages of 3 (1 x 3).   \n                   Bottles of 30 NDC 55111-154-30 \n                   Bottles of 100 NDC 55111-154-01 \n                   Bottles of 500 NDC 55111-154-05 \n                   Unit Dose Packages of 100 (10 x 10) NDC 55111-154-78 \n                  Unit Dose Packages of 3 (1 x 3) NDC 55111-154-13   \n                   Ondansetron tablets USP, 16 mg (ondansetron hydrochloride USP, equivalent to 16 mg of ondansetron) are white, round, biconvex, film coated tablets debossed “R” on one side and “155” on other side and are supplied in bottles of 30, 500 and unit-dose packages of 100 (10 x 10).   \n                   Bottles of 30 NDC 55111-155-30 \n                   Bottles of 500 NDC 55111-155-05 \n                  Unit-dose packages of 100 (10x10) NDC 55111-155-78   \n                   Ondansetron tablets USP, 24 mg (ondansetron hydrochloride USP, equivalent to 24 mg of ondansetron) are pink, round, biconvex, film coated tablets debossed “R” on one side and “156” on other side and are supplied in bottles of 30, 500, unit-dose packages of 100 (10 x 10) and unit-dose packages of 1 (1 x 1).   \n                  Bottles of 30 NDC 55111-156-30 \n                  Bottles of 500 NDC 55111-156-05 \n                  Unit Dose Packages of 100 (10 x 10) NDC 55111-156-78 \n                   Unit Dose Packages of 1 (1 x 1) NDC 55111-156-11   \n                   Store at 20°-25°C (68°-77°F) (See USP Controlled Room Temperature). Dispense in tight container as defined in the USP. Store blisters in cartons.",
    "adverseReactions": "Ondansetron is contraindicated in patients: \n                  \n                     known to have hypersensitivity (e.g., anaphylaxis) to ondansetron or any of the components of the formulation [see Adverse Reactions (6.2)]\n                     \n                     receiving concomitant apomorphine due to the risk of profound hypotension and loss of consciousness"
}